URL copied
Delhi s Sir Gangaram hospital begins monoclonal antibody therapy for COVID patients
Delhi s Sir Gangaram hospital on Tuesday started carrying out monoclonal antibody therapy, which is believed to reduce chance of hospitalisation for COVID-19 patients by 70 per cent.
As part of this single dose infusion-based treatment, patients with mild to moderate symptoms are offered a cocktail of Casirivimab and Imdevimab.
A dose will cost Rs 59,750, chairman of Sir Gangaram hospital, D.S. Rana, said.
Fortis Escorts Heart Institute (FEHI) chairman Ashok Seth said this therapy is meant for people who are under home isolation, and do not need oxygen support, so the cut-off level of SpO2 is about 93 per cent, and are at high risk due to their co-morbidities such as liver disease, heart ailments or chronic lung disease.
Monoclonal antibody drug production in India at reasonable price could be a game changer for the country in its fight against COVID-19, said Dr Arvinder S Soi
New Delhi [India], May 30 (ANI): Monoclonal antibody drug production in India at reasonable price could be a "game changer" for the country in its fight against COVID-19, said Dr Arvinder S Soin, Chairman, Institute of Liver Transplant and Regenerative Medicine at Medanta Hospital on Sunday.
India News: NEW DELHI: Last week, an 84-year-old man from Haryana was administered the "famous" anti-Covid cocktail that was also given to former US President Don.
The therapy is a mix of two ‘monoclonal antibodies’, or proteins, that are artificially created in a laboratory and tailor-made to fight a particular disease, in this cases, Covid-19